The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

At $25.60, Pfizer (NYSE:PFE | PFE Price Prediction) sits in Hold territory on Wall Street’s consensus. The headline 6.7% ...

The biotech company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage Chi ...

Hympavzi is approved for routine prophylaxis to prevent bleeding episodes in US patients six years and above.

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the ...